Philip C Johnston1,2, Laurence Kennedy3, Amir H Hamrahian3,4, Zahrae Sandouk3, James Bena5, Betul Hatipoglu3, Robert J Weil6,7. 1. Department of Endocrinology, Diabetes and Metabolism, Cleveland Clinic, 9500 Euclid Avenue Desk F20, Cleveland, OH, 44195, USA. pcjohnston@doctors.org.uk. 2. Regional Center for Endocrinology and Diabetes, Royal Victoria Hospital, Grosvenor Road, Belfast, UK. pcjohnston@doctors.org.uk. 3. Department of Endocrinology, Diabetes and Metabolism, Cleveland Clinic, 9500 Euclid Avenue Desk F20, Cleveland, OH, 44195, USA. 4. Department of Endocrinology, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates. 5. Department of Biostatistics, Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA. 6. Department of Neurosurgery, the Neurological Institute, Cleveland Clinic, Cleveland, OH, USA. 7. National Clinical Enterprise, Catholic Health Initiatives, Englewood, CO, USA.
Abstract
CONTEXT: Transsphenoidal surgery (TSS) to resect a pituitary adenoma is considered first-line treatment for patients with Cushing's disease (CD). Early, post-operative remission rates >80% are expected for patients with a microadenoma (≤ 10 mm) visible on magnetic resonance (MR) imaging. OBJECTIVE: To report surgical outcomes and predictors of remission in a specialist center for patients with CD. PATIENTS AND METHODS: Clinical data was obtained from a prospective CD database in addition to review of all electronic medical, laboratory and surgical patient records. Patients who underwent their first TSS by one neurosurgeon between 2004 and 2013, and had a minimum 1 year follow up, were evaluated. RESULTS: One hundred and one consecutive patients with CD (73F, 28M) underwent TSS. Median (range) age and follow-up were 47 (15-87) and 4.33 (1-9.8) years, respectively. At surgery, 74 (73.2%) patients had a microadenoma, 27 a macroadenoma; six of the latter patients had a planned, subtotal resection to control neurological signs due to mass effect. Initial remission rates were: microadenoma, 89% (66/74); macroadenoma, 63% (17/27); and 81% (17/21) in those macroadenomas where complete surgical removal was anticipated. Initial non-remission occurred in 18 patients, ten macro- and eight microadenoma; six of 18 had residual disease on most recent follow up. Six (2 macro, 4 micro) of the 83 patients with initial remission have had late (>12 months) recurrence of hypercortisolism that required either repeat TSS or adjunctive therapy, three of whom have persistent hypercortisolism. Macroadenoma (p = 0.003) and tumor invasion beyond the pituitary and sella (p < 0.001) were associated with failure to obtain remission with the initial TSS and greater likelihood of late recurrence. Patients in whom no lesion was seen on neuroimaging had rates of initial remission (21/25 or 84%) and a similar late recurrence rate of 4% (1/25) in comparison with those with MR-visible microadenomas (3/49, or 6%). CONCLUSIONS: A team-based approach, in a specialized pituitary center, can lead to initial and durable, long-term remission in patients with CD. The presence of a macroadenoma and tumor extension beyond the pituitary and sella were predictive of initial non-remission as well as risk of late recurrence.
CONTEXT: Transsphenoidal surgery (TSS) to resect a pituitary adenoma is considered first-line treatment for patients with Cushing's disease (CD). Early, post-operative remission rates >80% are expected for patients with a microadenoma (≤ 10 mm) visible on magnetic resonance (MR) imaging. OBJECTIVE: To report surgical outcomes and predictors of remission in a specialist center for patients with CD. PATIENTS AND METHODS: Clinical data was obtained from a prospective CD database in addition to review of all electronic medical, laboratory and surgical patient records. Patients who underwent their first TSS by one neurosurgeon between 2004 and 2013, and had a minimum 1 year follow up, were evaluated. RESULTS: One hundred and one consecutive patients with CD (73F, 28M) underwent TSS. Median (range) age and follow-up were 47 (15-87) and 4.33 (1-9.8) years, respectively. At surgery, 74 (73.2%) patients had a microadenoma, 27 a macroadenoma; six of the latter patients had a planned, subtotal resection to control neurological signs due to mass effect. Initial remission rates were: microadenoma, 89% (66/74); macroadenoma, 63% (17/27); and 81% (17/21) in those macroadenomas where complete surgical removal was anticipated. Initial non-remission occurred in 18 patients, ten macro- and eight microadenoma; six of 18 had residual disease on most recent follow up. Six (2 macro, 4 micro) of the 83 patients with initial remission have had late (>12 months) recurrence of hypercortisolism that required either repeat TSS or adjunctive therapy, three of whom have persistent hypercortisolism. Macroadenoma (p = 0.003) and tumor invasion beyond the pituitary and sella (p < 0.001) were associated with failure to obtain remission with the initial TSS and greater likelihood of late recurrence. Patients in whom no lesion was seen on neuroimaging had rates of initial remission (21/25 or 84%) and a similar late recurrence rate of 4% (1/25) in comparison with those with MR-visible microadenomas (3/49, or 6%). CONCLUSIONS: A team-based approach, in a specialized pituitary center, can lead to initial and durable, long-term remission in patients with CD. The presence of a macroadenoma and tumor extension beyond the pituitary and sella were predictive of initial non-remission as well as risk of late recurrence.
Entities:
Keywords:
Cushing’s syndrome; Remission; Single center experience; Transsphenoidal surgery
Authors: R van der Pas; C de Bruin; F W G Leebeek; M P M de Maat; D C Rijken; A M Pereira; J A Romijn; R T Netea-Maier; A R Hermus; P M J Zelissen; F H de Jong; A J van der Lely; W W de Herder; S W J Lamberts; L J Hofland; R A Feelders Journal: J Clin Endocrinol Metab Date: 2012-01-25 Impact factor: 5.958
Authors: Jay Jagannathan; Rene Smith; Hetty L DeVroom; Alexander O Vortmeyer; Constantine A Stratakis; Lynnette K Nieman; Edward H Oldfield Journal: J Neurosurg Date: 2009-09 Impact factor: 5.115
Authors: Ivan Ciric; Jin-Cheng Zhao; Hongyan Du; James W Findling; Mark E Molitch; Roy E Weiss; Samuel Refetoff; William D Kerr; Joel Meyer Journal: Neurosurgery Date: 2012-01 Impact factor: 4.654
Authors: Guy B Mulligan; Esin Eray; Charles Faiman; Manjula Gupta; Maria M Pineyro; Antoine Makdissi; John H Suh; Thomas J Masaryk; Richard Prayson; Robert J Weil; Amir H Hamrahian Journal: Endocr Pract Date: 2011 Jan-Feb Impact factor: 3.443
Authors: Jessica K Lambert; Levana Goldberg; Sofia Fayngold; Jane Kostadinov; Kalmon D Post; Eliza B Geer Journal: J Clin Endocrinol Metab Date: 2013-02-07 Impact factor: 5.958
Authors: Antonio Di Ieva; Fabio Rotondo; Luis V Syro; Michael D Cusimano; Kalman Kovacs Journal: Nat Rev Endocrinol Date: 2014-05-13 Impact factor: 43.330
Authors: Min Lang; Ghaith Habboub; Doksu Moon; Abin Bandyopadhyay; Danilo Silva; Laurence Kennedy; Varun R Kshettry; Pablo F Recinos Journal: J Neurol Surg B Skull Base Date: 2018-05-10
Authors: Elena Y Nadezhdina; Olga Yu Rebrova; Andrey Y Grigoriev; Oksana V Ivaschenko; Vilen N Azizyan; Galina A Melnichenko; Ivan I Dedov Journal: Pituitary Date: 2019-12 Impact factor: 4.107
Authors: Jordan E Perlman; Philip C Johnston; Ferdinand Hui; Guy Mulligan; Robert J Weil; Pablo F Recinos; Divya Yogi-Morren; Roberto Salvatori; Debraj Mukherjee; Gary Gallia; Laurence Kennedy; Amir H Hamrahian Journal: J Clin Endocrinol Metab Date: 2021-04-23 Impact factor: 5.958
Authors: Jessica W Grayson; Agnish Nayak; Mark Winder; Benjamin Jonker; Raquel Alvarado; Henry Barham; Ann McCormack; Richard J Harvey Journal: J Neurol Surg B Skull Base Date: 2019-10-21
Authors: Congxin Dai; Ming Feng; Lin Lu; Bowen Sun; Yanghua Fan; Xinjie Bao; Yong Yao; Kan Deng; Renzhi Wang; Jun Kang Journal: Front Oncol Date: 2022-02-08 Impact factor: 6.244
Authors: Christopher Beynon; Andreas Unterberg; Moritz Scherer; Paul Zerweck; Daniela Becker; Lars Kihm; Jessica Jesser Journal: Neurosurg Rev Date: 2022-05-14 Impact factor: 2.800